GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » Net Income Including Noncontrolling Interests

Financiere de Tubize (LTS:0D53) Net Income Including Noncontrolling Interests : €88.15 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Financiere de Tubize Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Financiere de Tubize's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was €-2.92 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was €88.15 Mil.


Financiere de Tubize Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Financiere de Tubize's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize Net Income Including Noncontrolling Interests Chart

Financiere de Tubize Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 283.70 260.52 83.60 85.17 88.15

Financiere de Tubize Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -121.22 87.27 -2.10 91.07 -2.92

Financiere de Tubize Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €88.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Financiere de Tubize Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Financiere de Tubize (LTS:0D53) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » Net Income Including Noncontrolling Interests
Traded in Other Exchanges
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (LTS:0D53) Headlines

No Headlines